Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON OLE: Open-label Extension Trial of HZN-825 in Diffuse Cutaneous Systemic Sclerosis
jRCT2011230044Completed
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of fipaxalparant in systemic sclerosis (SSc), sponsored by Horizon Therapeutics. Started Nov 2023; status: completed.
02
Drugs
fipaxalparant
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2011230044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011230044.